COMMUNIQUÉS West-GlobeNewswire

Nyxoah to Participate in the Jefferies Global Healthcare Conference
03/06/2024
Nyxoah to Participate in the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical [...]
Nyxoah Participera à la Conférence Jefferies Global Healthcare
03/06/2024
Nyxoah Participera à la Conférence Jefferies Global Healthcare Mont-Saint-Guibert, Belgique – 3 juin 2024, 22h30 CET / 16h30 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») opère dans le [...]
Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
03/06/2024
Call scheduled for Tuesday, June 4, 2024 at 8:30 a.m. ET BRISBANE, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement- [...]
American Oncology Network Appoints David Afshar as Chief Financial and Operating Officer
03/06/2024
Veteran Financial Leader David Afshar will lead the company’s financial and operating strategy. FORT MYERS, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- American Oncology Network (AON) (Nasdaq: AONC), one of the nation’s [...]
Arvinas to Participate in Upcoming Investor Conferences
03/06/2024
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that [...]
Aptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
03/06/2024
SAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral [...]
First of Its Kind Beverage that Reduces Blood Alcohol Content Safety Shot Partners with Mr. Checkout to Expand Presence with Independent Retailers Nationwide
03/06/2024
The Partnership Aims to Provide More Access For Consumers In Diversified Retail Locations JUPITER, FL, June 03, 2024 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) (the “Company), announced today its strategic [...]
Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3
03/06/2024
ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard- [...]
Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […]
03/06/2024
ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients atteints d’un myélome multiple nouvellement diagnostiqué, [...]
Information on the total number of voting rights and shares
03/06/2024
REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), June 3, 2024, 10:15 pm CET / 4:15 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the [...]
Informations sur le nombre total de droits de vote et d'actions
03/06/2024
INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 3 juin 2024, 22:15h CET / 16:15h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
DARZALEX® (daratumumab)-based regimens significantly improved clinical outcomes in both transplant-eligible and -ineligible patients who are newly diagnosed with multiple myeloma
03/06/2024
88 percent of transplant-eligible patients achieved a complete response or better, and 47 percent of patients sustained MRD-negativity for longer than one year with daratumumab subcutaneous formulation-based regimens in [...]
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
03/06/2024
FOSTER CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage biopharmaceutical company developing a portfolio of small molecule product [...]
Structure Therapeutics Announces Proposed Public Offering of American Depositary Shares and Pre-Funded Warrants
03/06/2024
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and [...]
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
03/06/2024
REDWOOD CITY, Calif., June 03, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) (“Biomea” or the “Company”), a clinical stage biopharmaceutical company focused on the discovery and development of covalent [...]
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
03/06/2024
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that Genetics in Medicine , an official journal of the [...]
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03/06/2024
BOSTON, June 03, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on May 31, 2024, the [...]
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
03/06/2024
FibroGen to evaluate FG-3165, an anti-galectin 9 (Gal9) monoclonal antibody (mAb), as monotherapy treatment as well as in combination with LIBTAYO ® in patients with select solid tumors FibroGen to evaluate FG-3175, an [...]
Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
03/06/2024
CAMBRIDGE, Mass., June 03, 2024 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare [...]

Pages